Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
No dosage increase required
Beyond the obesity data, the Phase 3 study ACHIEVE-1 in people with early type 2 diabetes over 40 weeks documented an HbA1c change of -1.24, -1.47, and -1.48 percentage points at 3, 12, and 36 mg, versus -0.41 percentage points under placebo (Fras et al., NEJM 2025)
These side effects were less severe when participants gradually built up to a full dose of maridebart cafraglutide, which may be the best way to get people started on it in the future
10.52418/moldovan-med-j.66-2.23.04 38
US$ 20.29
US$ 26.18
US$ 20.71
US$ 24.05
US$ 28.11
US$ 24.74
US$ 22.42
